DelMar Pharmaceuticals, Inc.
12707 High Bluff Dr., Suite 200
San Diego, CA 92130
June 30, 2020
VIA EDGAR
United States Securities and Exchange Commission
Division of Corporation Finance
100 F Street, N.E.
Washington, D.C. 20549
| Re: | DelMar Pharmaceuticals, Inc. (the “Company”) |
Registration Statement on Form S-4 (File No. 333-239215) |
Ladies and Gentlemen:
In accordance with Rule 461 under the Securities Act of 1933, as amended, the Company hereby requests that the above-referenced Registration Statement (the “Registration Statement”) be declared effective by the Securities and Exchange Commission at 4:15 p.m., Eastern Time, on July 2, 2020, or as soon as practicable thereafter.
Please call Michael J. Lerner of Lowenstein Sandler LLP at (973) 597-6394 to confirm the effectiveness of the Registration Statement or with any questions.
[Signature page follows.]
U.S. Securities and Exchange Commission
June 30, 2020
Page 2
Very truly yours,
DELMAR PHARMACEUTICALS, INC.
By: /s/ Scott Praill
Name: Scott Praill
Title: Chief Financial Officer
